Clinical Trial: Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
Study Status: Completed
Recruit Status: RECRUITING
Condition: Triple Negative Breast Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
Brief Summary:
A first-in-human study using BDC-3042 as a single agent and in combination with pembrolizumab in patients with advanced malignancies
Read more